James Van Etten is the William Allington Distinguished Professor of Plant Pathology at the University of Nebraska-Lincoln, affiliated with the School of Biological Sciences and Nebraska Center for Virology. His research focuses on chloroviruses—large dsDNA viruses infecting Chlorella-like algae—with emphasis on DNA replication, restriction systems, and membrane transport proteins. Key research themes include: Viral DNA modification systems Host-virus interactions Structural virology Evolution of organellar genomes Recent work analyzed: SMRT sequencing of viral methylation patterns Chlorovirus cryopreservation methods Potassium channel biophysics Host chemical signaling mechanisms Lab webpage: vanettenlab.unl.edu
Jennifer Curtis is a Full Professor in the School of Physics at Georgia Institute of Technology and serves as an ADVANCE Professor for the College of Sciences. Her research focuses on the physics of cell-cell and cell-extracellular matrix interactions, particularly within glycobiology and immunobiology contexts. Dr. Curtis earned her Ph.D. in Physics from the University of Chicago (2002) and her B.A. in Physics from Columbia University (1997). Her research interests span biophysics at interfaces, quantitative modeling of collective cellular interactions, cell mechanics, motility, adhesion, and the role of bulky sugars in tissue organization. Her laboratory investigates collective and single cell migration, immunophage therapy (combining immune cells with phages to combat bacterial infections), and molecular biophysics of hyaluronan synthase. Recent work demonstrates applications in soft materials, biomaterials, tissue engineering, and advanced characterization techniques. Analysis of her publication record reveals consistent focus on glyco-biophysics and cellular mechanics, with increasing emphasis on microbial communities and therapeutic applications. Her work bridges physics, biology, and engineering through interdisciplinary approaches. Honors include the NSF CAREER Award (2010), Georgia Tech College of Sciences Faculty Mentor Award (2015), and Cullen Peck Award (2020). She serves on the Biophysical Journal editorial board. Dr. Curtis actively mentors students through the Georgia Tech Physics REU program (which she directs) and collaborates with biologists, chemists, and materials scientists. Her laboratory maintains strong partnerships with institutions including Emory University and international collaborators. The Curtis Lab operates the Cell Physics Laboratory in the Molecular Science & Engineering Building, utilizing advanced techniques including holographic optical tweezers, thermochemical nanolithography, and single-molecule imaging to study cellular mechanics and polymer physics at biological interfaces.
Professor Christopher Roland is a faculty member in the Department of Physics at North Carolina State University, part of the College of Sciences. He holds the rank of Professor since 2002, joining the university in 1993 after completing his PhD in Physics at McGill University, Canada, and postdoctoral work at the University of Toronto and AT&T Bell Laboratories. His research focuses on theoretical condensed matter physics and biophysics, particularly investigating nucleic acid structures (DNA and RNA) associated with neurodegenerative and neuromuscular disorders like Trinucleotide Repeat Expansion Diseases (TREDs). Key areas include DNA/RNA hairpin dynamics, free energy calculations, and molecular mechanisms underlying genetic mutations. Recent publications emphasize structural and computational studies of nucleic acid conformations, such as Z-DNA motifs, triplex formations, and disease-linked repeat sequences. His work bridges quantum transport simulations, biomolecular modeling, and disease prediction. No scientific awards are explicitly listed in the provided materials. His research is supported by grants from NC State University and collaborations within the Department of Physics. Laboratory and team details are not specified, though his work aligns with computational biophysics and condensed matter research groups at NC State.
Dr. Xi Chen is a Professor in the Department of Chemistry at the University of California, Davis, where he has been a faculty member since 2003. His research spans carbohydrate chemistry, glycobiology, and cancer biology, with notable contributions to chemoenzymatic methods for glycoconjugate synthesis. Dr. Chen's work focuses on developing hybrid chemical-enzymatic approaches to synthesize complex carbohydrates and glycoconjugates, characterizing glycosyltransferase mechanisms, and designing enzyme mutants for improved catalysis. He also investigates carbohydrate-based diagnostics and therapeutics, particularly in cancer and inflammatory diseases. His recent publications highlight interdisciplinary studies linking carbohydrate metabolism to p53 tumor suppression pathways and RNA-binding protein regulation in cancer. Awards include AAAS Fellow (2015), ACS Isbell Award (2012), and NSF CAREER Award (2006). He earned his Ph.D. at Wayne State University (2000) and B.S. at Xiamen University (1994). Scientific Awards American Association for the Advancement of Science Fellow (2015) Dean's Team Award for Excellence (2013) Carbohydrate Research Award for Creativity (2013) ACS CARB Horace S. Isbell Award (2012)
University of California, Los AngelesUnited States
Jeff S Abramson is a Professor of Physiology in the David Geffen School of Medicine at the University of California Los Angeles (UCLA). His research focuses on the structural and functional characterization of membrane transport proteins, particularly sugar transporters and mitochondrial channels. He maintains an active laboratory investigating the molecular mechanisms of cellular transport processes. Dr. Abramson's primary research interests center on membrane transport proteins, with particular emphasis on sugar symporters and voltage-dependent anion channels (VDACs). His work combines structural biology, biophysics, and biochemistry to understand the molecular mechanisms of transport, including conformational changes during transport cycles, substrate recognition, and regulation by membrane potential. His research has significant implications for understanding metabolic disorders, mitochondrial function, and potential therapeutic targets. Analysis of Dr. Abramson's publication record reveals a consistent focus on membrane protein structure-function relationships over the past two decades. His work demonstrates expertise in X-ray crystallography, cryo-electron microscopy, and functional assays to characterize transport proteins. Recent publications show increasing emphasis on mitochondrial biology, particularly VDAC structure and function, while maintaining his longstanding interest in sugar transport mechanisms. His research bridges fundamental biophysical principles with potential biomedical applications in metabolic diseases. Dr. Abramson has been awarded multiple NIH grants supporting his research, including the R35GM135175 grant titled 'Deciphering molecular details of cellular sugar transport and their roles in disease' (2020-2024), R01GM124783 'Functional and structural studies of unique pathogenic transporters involved in glycobiology' (2017-2021), and R01GM078844 'Structural and functional characterization of sugar transporters in health and disease' (2006-2020). As Principal Investigator, Dr. Abramson has mentored numerous graduate students and postdoctoral researchers. His laboratory has made significant contributions to understanding the structure-function relationships of membrane transport proteins through collaborations with researchers across multiple disciplines. The lab utilizes advanced techniques including X-ray crystallography, cryo-EM, electrophysiology, and computational modeling to address fundamental questions about membrane protein mechanisms. Dr. Abramson's laboratory is part of UCLA's broader research ecosystem focused on structural biology and membrane protein research. His work intersects with several research centers at UCLA including those focused on metabolic diseases and structural biology. The lab maintains active collaborations with researchers specializing in biophysics, computational modeling, and disease mechanisms to translate basic findings into potential biomedical applications.
Scott Garman is Professor of Biochemistry at UMass Amherst, focusing on structural biology of glycoproteins in human diseases. PhD from Harvard University. Research areas: Lysosomal enzyme mechanisms in storage diseases (Fabry, Schindler); Malaria surface protein structures; Antibody-receptor interactions. Utilizes X-ray crystallography to study enzyme mutations causing disease. Key findings: Determined structures of α-galactosidase (Fabry disease) and α-NAGAL (Schindler disease), revealing molecular bases for enzyme dysfunction. Developed models for enzyme trafficking and substrate processing. Laboratory: Investigates protein folding diseases and develops therapeutic strategies. Collaborates on malaria vaccine development and antibody engineering.
Professor Tillman U. Gerngross is a faculty member at the Thayer School of Engineering at Dartmouth College, where he holds the rank of Professor of Engineering. His research focuses on protein engineering, glycoprotein engineering, and metabolic engineering, with significant contributions to yeast-based production systems for therapeutic proteins. He has pioneered technologies for humanizing glycosylation pathways in yeast, enabling the production of complex glycoproteins for biomedical applications. Education: BS/MS in Chemical Engineering (1989) and PhD in Molecular Biology (1991), both from the Technical University of Vienna, Austria. Research Interests: Professor Gerngross’s work bridges biotechnology and engineering, emphasizing scalable production methods for biologics. His lab has developed novel fermentation and protein expression systems, with applications in antibody engineering and metabolic pathway optimization. Awards: Member of the National Academy of Engineering (2017), 2013 National Academy of Inventors Fellow, and recipient of the 2020 Dartmouth Entrepreneurs Forum Technology Innovation Award. Entrepreneurial Ventures: Co-founder of multiple biotech companies, including GlycoFi (acquired by Merck for $400M), Adimab, Alector, Avitide (acquired by Repligen), and Adagio Therapeutics. These ventures focus on antibody discovery, cancer therapeutics, and pandemic response technologies. Grants & Funding: His startups have secured substantial funding through venture capital and strategic partnerships, reflecting their commercial viability and scientific impact. Notable milestones include Avitide’s $150M acquisition and Alector’s $2.2B valuation post-IPO. Labs & Teams: Leads a multidisciplinary research group at Thayer, collaborating with industry partners to translate academic discoveries into industrial applications. His companies employ advanced R&D teams to develop therapies and biomanufacturing solutions.
Dr. Alexandre Marques is an Assistant Professor at the University of Southern Mississippi. His expertise spans Microbiology, Immunology, and Parasitology, with a focus on vaccine development against parasitic infections like Leishmaniasis, Chagas disease, and Malaria. He holds a PhD from the Universidade de São Paulo (2007) and teaches courses such as Gen Microbiology and Microorg Hth Di at the university. His research integrates immunological, clinical, and molecular approaches to understand parasitic disease mechanisms and therapeutic interventions. Notable areas include α-Gal immunization strategies, transcriptomic analysis of breast cancer, and vaccine design against Leishmania. He has also explored applications in aquaculture nutrition and cosmetic safety assessments. Dr. Marques’ work spans interdisciplinary collaborations, including veterinary medicine, nanotechnology-based drug delivery, and antimicrobial stewardship in pediatrics. His contributions to animal models for Chagas disease and canine visceral leishmaniasis highlight translational research impact. Key themes in his publications include immune response modulation, pathogen-host interactions, and biomarker discovery in chronic infections. He has published over 50 articles across microbiology, immunology, and biomedical engineering since 2007.
Jacob Hatvany is an Assistant Professor in the Department of Chemistry & Biochemistry at Harding University. His research focuses on analytical chemistry, particularly in advancing mass spectrometric techniques for carbohydrate and glycoconjugate analysis. Ph.D. in Chemistry, Baylor University (2019-2024) B.S. in Chemistry, Harding University (2013-2017) Dr. Hatvany’s work explores hydrogen/deuterium exchange, microdroplet reactions, and electrospray ionization to enhance the structural characterization of carbohydrates and peptides. His studies often address how pH influences ionization dynamics and isomer differentiation. His research output includes peer-reviewed articles in Journal of the American Society for Mass Spectrometry , Carbohydrate Research , and Mass Spectrometry Reviews , along with a doctoral thesis on hydrogen/deuterium exchange methodologies. Ron Hites Award (2022) Dr. Hatvany has contributed to foundational work in carbohydrate analysis, with grants and collaborations supporting his studies on metal adduction and rapid exchange techniques.
Jennifer Golden is an Associate Professor in the Department of Pharmaceutical Sciences at the School of Pharmacy , University of Wisconsin-Madison . Her research focuses on synthetic medicinal chemistry to develop novel antiviral and anti-parasitic agents for diseases like alphavirus infections and kinetoplastid parasites. The Golden Lab emphasizes chemical methodology development and structure-activity relationship analysis through collaborations assessing compound efficacy in cell and animal models . Research Projects Quinazolinone Rearrangement: Developing synthetic transformations for amidine formation and ring-fused scaffolds. Anti-Alphaviral Agents: Creating FDA-approved therapeutic candidates for mosquito-borne RNA viruses. Broad-Spectrum Antiparasitics: Optimizing compounds for malaria, African sleeping sickness, and leishmaniasis. Publications highlight her work on ML336 (anti-VEEV), quinazolinone derivatives , and collaborations with experts in high-throughput screening and structural biology . Her lab trains students in hit-to-lead optimization , regioselective synthesis , and medicinal chemistry tactics . Education: B.S. (1996) – Eastern Illinois University Ph.D. (2002) – University of Kansas Postdoctoral Research (2004) – Stanford University
Catherine E. Costello is the William Fairfield Warren Distinguished Professor and Director of the Center for Biomedical Mass Spectrometry Education at Boston University School of Medicine. She holds a PhD and MS from Georgetown University. Her research focuses on biopolymer structural studies and mass spectrometry method development, particularly in glycobiology. Her lab is an NIH-funded Resource Center advancing glycan characterization and structural analysis. Key research interests include carbohydrate conjugate analysis, glycoproteomics, and applications in disease mechanisms like cancer, infection, and immune response. Collaborations span institutions globally, addressing complex biomolecules and their roles in health and disease. Recent publications highlight advancements in glycoproteomic characterization, ion mobility spectrometry, and glycan identification. Awards include the distinguished professor title. Lab members include postdoctoral associates, research staff, and visiting scientists from institutions like MGH and Nutricia Research.
Hien Nguyen is the Carl Johnson/Pfizer Professor of Organic Chemistry at Wayne State University, holding joint appointments in the Department of Chemistry and the Department of Oncology's Molecular Therapeutic Program. His research program bridges chemistry and biology to develop novel therapeutic approaches for cancer, Alzheimer's disease, and diabetes through innovative carbohydrate chemistry. His educational background includes: B.S. in Chemistry from Tufts University (1996) Ph.D. in Organic Chemistry from University of Illinois at Urbana-Champaign (2003) NIH Postdoctoral Fellowship at Stanford University (2003-2006) Prof. Nguyen's research focuses on medicinal chemistry, cancer drug discovery, chemical biology, and organic synthesis, with particular expertise in vaccine adjuvant immunotherapy, Alzheimer's disease therapeutics, diabetes treatments, and catalytic stereoselective carbohydrate methods. His lab develops novel methodologies for oligosaccharide assembly and applies them to create carbohydrate-based therapeutics targeting heparanase and other biological pathways involved in disease progression. His recent publications demonstrate a strong focus on phenanthroline-catalyzed stereoselective glycosylations, heparan sulfate mimetics for therapeutic applications, transition-metal catalyzed asymmetric synthesis, and the development of carbohydrate-based inhibitors for heparanase. These works span organic chemistry methodology, medicinal chemistry, and biochemical applications, reflecting his interdisciplinary approach to solving complex biological problems through chemical innovation. Among his notable awards are: 2018 Carl Johnson Endowed Chair 2018 Horace S. Isbell Award for Excellence in Carbohydrate Research 2016 Mitzutani Glycoscience Innovation Award 2012 International Young Carbohydrate Investigator Award Prof. Nguyen has successfully mentored numerous graduate students and postdoctoral fellows who have gone on to successful careers in academia and industry. His research is supported by multiple NIH grants including R01AI169505 "Synthesis and Evaluation of Carbohydrate Vaccine Adjuvants" (2022-2027) and R35GM149213 "Development of Catalytic Glycosylations and Biologically Important Glycosaminoglycans" (2023-2028). His group actively pursues both fundamental methodology development and translational applications of carbohydrate chemistry. The Nguyen research group operates state-of-the-art organic synthesis and biochemical characterization facilities, with strong collaborations across Wayne State University including the School of Medicine. The group maintains active partnerships with researchers at other institutions and pharmaceutical companies to advance their therapeutic discoveries toward clinical applications.
University of Texas Southwestern Medical CenterUnited States
Marc Diamond, M.D. , is a Professor of Neurology and Neuroscience at UT Southwestern Medical Center. He previously served as the David Clayson Professor of Neurology at Washington University in St. Louis (2009-2014) and held faculty positions at UCSF (2002-2009). As founding director of the Center for Alzheimer's and Neurodegenerative Diseases (CAND), he leads a multidisciplinary team investigating protein aggregation mechanisms in neurodegenerative diseases. Education: M.D. from UCSF (1993), history degree from Princeton Key Contributions: Discovered cell-to-cell propagation of tau protein aggregates, linking Alzheimer's to prion biology His research focuses on tauopathies , prion-like protein propagation , and translational therapeutics . He has developed methods for detecting proteopathic seeding activity now used globally, holds multiple patents, and invented a monoclonal antibody in clinical trials for Alzheimer's therapy. His work has profoundly impacted understanding of neurodegenerative disease progression and therapeutic strategies. Laboratory: The Diamond Lab trains postdocs, graduate students, and staff in multidisciplinary approaches to neurodegeneration, emphasizing cellular models and molecular mechanisms of protein aggregation.
University of North Carolina at Chapel HillUnited States
Ronit Freeman, PhD is an Associate Professor in the Department of Applied Physical Sciences at the University of North Carolina at Chapel Hill , where she is also affiliated with the UNC Lineberger Comprehensive Cancer Center . Research Focus : Cellular response to extracellular matrix (ECM) cues across multiple length/time scales Methodologies : Synthetic biology, supramolecular chemistry, DNA/RNA aptamer technology Dr. Freeman's work develops reconfigurable ECM platforms to study and engineer cellular fate decisions through: Controllable biochemical and biomechanical signaling Advanced fibrous architecture design Dynamic topography and mechanics modulation Applications in cancer therapy, wound healing, and fibrosis reversal Key collaborations include: Shawn Hingtgen's lab - Therapeutic cell engineering RNA Discovery Center (led by Chad Pecot) Scientific Achievements: Recipient of Eshelman Institute for Innovation Award (2020) Gordon & Betty Moore Foundation Collaborative Innovation Award (2019) Scialog Fellow (2019) Multiple early-career fellowships (EMBO, Clore, Converging Technologies) Her interdisciplinary team combines expertise from chemistry, cell biology, synthetic biology, medicine, engineering, and physics to address cutting-edge bio-nanotechnology challenges.
Flora Meilleur serves as a Neutron Scattering Scientist at Oak Ridge National Laboratory (ORNL) working on the IMAGINE and MaNDi diffractometers (HFIR CG-4D and SNS BL-11B), and holds a joint appointment as Associate Professor in the Biochemistry Department at North Carolina State University since 2007. She joined ORNL in 2005 after completing her PhD and has been instrumental in developing neutron scattering capabilities for structural biology research. Dr. Meilleur earned her Ph.D. in Structural Biology from the European Molecular Biology Laboratory (EMBL) and Université Grenoble Alpes (Grenoble, France) in 2004. Prior to joining ORNL, she served as an instrument scientist at the Institut Laue Langevin (ILL) on the LADI diffractometer. She was promoted to Associate Professor at NCSU in 2015 and established a university consortium that secured NSF funding to build the IMAGINE instrument at HFIR in 2009, serving as lead scientist for this project from 2009-2017. Her research focuses on applying neutron scattering techniques to understand enzymatic mechanisms, particularly in cellulose-degrading enzymes including lytic polysaccharide monooxygenases. She leads projects on cellulose deconstruction for biofuel production, nylon depolymerization, and enzyme immobilization in biopolymer matrices. Her laboratory employs a multidisciplinary approach combining X-ray and neutron diffraction and scattering, DFT calculations, and isotopic labeling techniques to study protein structure, dynamics, and function. Current research includes characterizing nylon hydrolases in collaboration with Dr. Josh Michener and studying biopolymer matrices as part of the BIG collaboration funded by the Novo Nordisk Foundation. Analysis of Dr. Meilleur's recent publications reveals a consistent focus on advancing neutron scattering methodologies for structural biology, with particular emphasis on enzymatic mechanisms in biomass degradation. Her work spans fundamental method development (beamline instrumentation, sample environments) to biological applications (viral proteins, polymer-degrading enzymes). A notable trend is the expansion of neutron techniques to study challenging biological questions, including time-resolved studies and complex enzyme systems, with increasing applications to viral research as evidenced by her SARS-CoV-2 related publications. 2013 ORNL Significant Event Award (Team award for construction and commissioning of CG4-D beamline and IMAGINE instrument; Role: Science lead) Dr. Meilleur has mentored numerous graduate students and post-doctoral fellows who utilize small angle X-ray/neutron scattering, X-ray/neutron crystallography, and computational methods in their research. She serves as Editor for the Journal of Applied Crystallography (2015-present) and was appointed as a main editor in 2021. She also mentors for the IUCr Early Career Board (2025-present) and previously served as Secretary of the Neutron Scattering Society of America (2019-2022). She has organized and led the annual 'Neutrons in Structural Biology' workshop at ORNL since 2010, fostering community development in this specialized field. Dr. Meilleur leads the Meilleur lab at NC State which focuses on structural enzymology using neutron scattering techniques. Her laboratory collaborates extensively with researchers at ORNL's High Flux Isotope Reactor and Spallation Neutron Source facilities. She has served on multiple professional committees including the SNS/HFIR user committee (SHUG) from 2007-2009 and as a member-at-large of the NSSA between 2008-2012, demonstrating sustained leadership in the neutron scattering community.
